



www.genfit.com

**GENFIT: CONVERSIONS INTO SHARES OF 70 BONDS
OCA2012-2 AND IMPLEMENTATION OF THE SIXTH
INSTALLMENT (€1 M) OF THE RESERVED CONVERTIBLE
BOND LOAN AGREEMENT OF €8 M**

- **70 of the 100 OCA2012-2 bonds as part of the 5th installment have been converted into shares by the Bondholder.**
- **At GENFIT's initiative, implementation of one of the 7 notes redeemable for bonds convertible into shares (BEOCA2012), giving access to a 6th €1 M convertible bond loan.**

Lille (France), Boston (Massachusetts, United States), March 27, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces that it has requested the implementation of the sixth installment of €1 M of the €8 M bond loan agreement, convertible into ordinary Company shares, signed on December 20th, 2012, as well as the conversion into shares of 70 of the 100 bonds as part of the 5th installment, in keeping with the 1st and 2nd resolutions of the Extraordinary Shareholders' Meeting of December 18th, 2012 ("the Assembly").

In keeping with these resolutions and with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd ("the Bondholder"), GENFIT's Management Board, by its decision of March 25th, 2013, decided to authorize the Bondholder to implement the 5th of the 7 notes redeemable for bonds convertible into shares ("BEOCA2012"), giving access to 100 new OCA2012-2 bonds, convertible into shares under the same conditions as the first such bonds.

The Management Board having decided to implement this 6th €1 M installment, a commitment fee of approximately 5% of the value of this new installment (€50,000), has been paid to the Bondholder in ordinary Company shares with an issue price of €5.22, issue premium included, in keeping with the second resolution of the Extraordinary Shareholders' Meeting of December 18th, 2012, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five (5) trading days (March 19-25, 2013) prior to the decision to pay this commitment fee. As a result, 9,578 new shares immediately assimilated with existing shares have been subscribed by the Bondholder to offset this commitment fee.

In keeping with the 1st and 2nd resolutions of the Assembly and with the convertible loan contract, the Bondholder moreover made three conversion requests on March 25th, 2013 of a total of 50 OCA2012-2 bonds as part of the 5th installment, then one further conversion request for 20 OCA2012-2 bonds on March 26th, 2013.

The conversion of 50 OCA2012-2 bonds on March 25th, 2013 into 97,820 new shares was performed at a conversion rate of €5.11, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five (5) trading days (March 18-22, 2013) prior to the conversion requests.

The conversion of 20 OCA2012-2 bonds on March 26th, 2013 into 38,284 new shares was performed at a conversion rate of €5.22, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five (5) trading days (March 19-25, 2013) prior to the conversion requests.

As a result of these conversions and reserved share issues to the Bondholder:

- The social capital of GENFIT has increased from €4,261,779.50 to €4,298,200;
- The number of shares representing the social capital of GENFIT has increased by 145,682, from 17,047,118 to 17,192,800 shares;
- The amount of the 5th installment of the bond loan agreement that remains to be converted is €170,000.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian
Ph. +331 7544 8740 / +336 8788 4726 – barabian@milestones.fr